Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
September 9th, 2021
2.9K views
Time-resolved Förster resonance energy transfer cell-based assay protocols are described for the simple, specific, sensitive, and robust quantification of endogenous phosphorylated signal transducer and activator of transcription (STAT) 1/3/4/5/6 proteins in cell lysates in a 384-well format.
Overview
This article describes time-resolved Förster resonance energy transfer (TR-FRET) cell-based assay protocols for quantifying endogenous phosphorylated STAT proteins in cell lysates. The assays are designed to be simple, specific, sensitive, and robust, utilizing a 384-well format.
Key Study Components
Area of Science
- Cell signaling
- Biochemistry
- Pharmacology
Background
- TR-FRET assays provide cost-effective tools for screening modulators of the JAK/STAT pathways.
- This technique is easier and more reproducible than conventional methods like Western blot and ELISA.
- No washing steps are required, simplifying the process.
- Specific antibodies are necessary for application to other signaling proteins.
Purpose of Study
- To develop a robust assay for quantifying phosphorylated STAT proteins.
- To provide a rapid and reproducible alternative to traditional methods.
- To facilitate the pharmacological characterization of JAK/STAT modulators.
Methods Used
- Time-resolved Förster resonance energy transfer (TR-FRET) assays.
- 384-well format for high-throughput screening.
- Single-step reagent addition without washing steps.
- Optimization of cell culture and treatment conditions.
Main Results
- TR-FRET assays demonstrated high sensitivity and specificity for STAT proteins.
- Assays were reproducible and robust across different experimental setups.
- Elimination of washing steps streamlined the assay process.
- Potential for application to other signaling proteins with appropriate antibodies.
Conclusions
- TR-FRET assays are a valuable tool for studying JAK/STAT signaling.
- The method enhances the efficiency of pharmacological screening.
- Good cell culture practices and standard operating procedures are essential for reproducibility.
Frequently Asked Questions
What is TR-FRET?
TR-FRET stands for time-resolved Förster resonance energy transfer, a technique used to measure interactions between proteins.
How does TR-FRET compare to Western blot?
TR-FRET is easier, faster, and does not require washing steps, making it more efficient than Western blot.
What are the advantages of using a 384-well format?
The 384-well format allows for high-throughput screening, enabling the analysis of multiple samples simultaneously.
Can TR-FRET assays be applied to other proteins?
Yes, TR-FRET assays can be adapted for other signaling proteins if specific antibodies are available.
What are the key considerations for assay reproducibility?
Good cell culture practices and established standard operating procedures are crucial for ensuring reproducibility.
Executive Industry Relevance
Quantitative measurement of endogenous phosphorylated STAT proteins is critical for de-risking JAK/STAT pathway modulation in early drug discovery. The TR-FRET platform enables robust, high-throughput, and reproducible detection of phospho-STAT isoforms, supporting predictive confidence in target engagement and pathway interrogation. This capability streamlines portfolio triage and accelerates the identification of selective modulators for oncology and immunology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct quantification of endogenous phospho-STAT proteins in native cellular contexts.
- Supports functional validation of JAK/STAT pathway modulation by candidate compounds.
- Facilitates mechanistic de-risking through ratiometric, quantitative readouts.
- Improves predictive confidence for advancing pathway-targeted assets.
Screening & Assay Development
- Delivers high-throughput, no-wash assays suitable for 384-well screening formats.
- Provides robust, reproducible, and scalable assay performance for compound evaluation.
- Enables rapid pharmacological profiling of agonists and inhibitors with validated Z'-factor metrics.
- Reduces assay variability and operational complexity compared to Western blot or ELISA.
Translational & Preclinical Research
- Aligns with disease-relevant pathway interrogation in oncology and immune models.
- Supports continuity from discovery through preclinical validation by enabling consistent phospho-protein measurement.
- Facilitates risk-adjusted advancement decisions based on quantitative pathway modulation data.
Pipeline & Workflow Integration
The TR-FRET assay platform integrates from early discovery through lead identification and preclinical validation, providing a reusable and adaptable capability for pathway-centric programs.
- Discovery Biology: Enables hypothesis testing and pathway clarification via direct phospho-STAT quantification.
- Screening: Supports assay readiness and reproducibility for high-throughput compound screening.
- Analytics: Delivers quantitative, ratiometric readouts for robust statistical comparison of conditions.
- Translational Research: Maintains biomarker alignment and continuity across model systems when supported by antibody availability.
- Enterprise Reuse: Platform can be extended to other signaling proteins with validated antibodies, enhancing R&D flexibility.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in pathway-targeted programs.
- Operational Value: Standardizes and streamlines assay workflows for reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of assets targeting JAK/STAT signaling.
Implementation Considerations
- Requires expertise in cell culture, assay optimization, and antibody validation.
- Needs access to TR-FRET compatible microplate readers and analytical infrastructure.
- Demands cross-team standardization of protocols and quality controls.
- Adaptation to other targets depends on availability of specific antibody pairs.
- Assay performance may be limited by cell line compatibility and phosphatase activity if not properly controlled.
Biopharma FAQs
Why does null hypothesis testing matter for phospho-STAT TR-FRET assays?
Null hypothesis testing ensures that observed changes in phospho-STAT levels are statistically significant and not due to assay variability or background noise. This is essential for validating target engagement and supporting confident advancement decisions in discovery programs.
How does independent variable isolation fit the JAK/STAT modulator screening workflow?
Isolating variables such as compound concentration and treatment time allows precise attribution of phospho-STAT modulation to specific interventions. This supports mechanistic de-risking and informs structure-activity relationship development in screening campaigns.
What do quantitative dependent variable measurements enable in TR-FRET STAT assays?
Quantitative measurement of phospho-STAT levels enables robust comparison of compound efficacy, potency, and selectivity. This facilitates data-driven prioritization and optimization of lead candidates targeting the JAK/STAT pathway.
Why are replication requirements critical for cross-functional assay deployment?
Replication ensures assay reproducibility and reliability across different operators, instruments, and sites. This is vital for cross-functional collaboration and for generating data that can be confidently used in portfolio decision-making.
What statistical analysis capabilities are required before TR-FRET assay implementation?
Robust statistical analysis, including calculation of Z'-factor, signal-to-background ratio, and coefficient of variation, is required to validate assay performance. These metrics ensure the assay meets industry standards for high-throughput screening and reliable data generation.
Chapters in this video
0:05
Introduction
1:02
Stimulator or Inhibitor Titration Using the Two-Plate Assay Protocol with Adherent Cells
4:33
Results: Two-Plate and One-Plate Detection of STAT Proteins in Adherent and Suspension Cell Lines, and Intraplate Variability Study
6:40
Conclusion
